Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio sul Diabete di Tipo 2 INtrattabile (CAPTAIN-T2D) (CAPTAIN-T2D)

5 ottobre 2026 aggiornato da: Sparrow Pharmaceuticals

Clofutriben e Placebo Studio di Fase 2 contro il Diabete di Tipo 2 Intrattabile (CAPTAIN-T2D)

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.

The trial consists of two parts.

Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.

During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.

Tipo di studio

Interventistico

Iscrizione (Stimato)

1500

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Arizona
      • Chandler, Arizona, Stati Uniti, 85225
        • Reclutamento
        • Arizona Clinical Trials - Pecos
        • Contatto:
      • Tucson, Arizona, Stati Uniti, 85711
    • California
      • Fountain Valley, California, Stati Uniti, 92708
        • Reclutamento
        • Ark Clinical Research - Fountain Valley
        • Contatto:
      • Huntington Park, California, Stati Uniti, 90255
      • La Mesa, California, Stati Uniti, 91942
      • Long Beach, California, Stati Uniti, 90815
      • Los Angeles, California, Stati Uniti, 90057
      • Los Angeles, California, Stati Uniti, 90015
        • Reclutamento
        • Los Angeles Institute for Metabolic Research
        • Contatto:
      • Northridge, California, Stati Uniti, 98433
      • San Diego, California, Stati Uniti, 92120
    • Florida
      • Edgewater, Florida, Stati Uniti, 32132
        • Reclutamento
        • Velocity Clinical Research, New Smyrna Beach
        • Contatto:
      • Fort Lauderdale, Florida, Stati Uniti, 33312
        • Reclutamento
        • The Center for Diabetes and Endocrine Care
        • Contatto:
      • Miami, Florida, Stati Uniti, 33173
      • New Port Richey, Florida, Stati Uniti, 34652
      • Port Charlotte, Florida, Stati Uniti, 33952
        • Reclutamento
        • Innovative Research Institute
        • Contatto:
      • Port Orange, Florida, Stati Uniti, 32127
      • Winter Park, Florida, Stati Uniti, 32789
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30303
        • Reclutamento
        • Emory University School of Medicine
        • Contatto:
      • Columbus, Georgia, Stati Uniti, 31904
    • Idaho
      • Boise, Idaho, Stati Uniti, 83709
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60607
        • Reclutamento
        • Chicago Clinical Research Institute
        • Contatto:
          • Manognya Clinical Research Manager
          • Numero di telefono: 303 3127913241
          • Email: manognya@ccrii.us
    • Iowa
      • West Des Moines, Iowa, Stati Uniti, 50226
        • Reclutamento
        • Iowa Diabetes and Endocrinology Research Center
        • Contatto:
    • Kansas
      • Wichita, Kansas, Stati Uniti, 67226
        • Reclutamento
        • Alliance for Multispecialty Research - Wichita East
        • Contatto:
    • Kentucky
      • Edgewood, Kentucky, Stati Uniti, 41017
    • Louisiana
      • Lafayette, Louisiana, Stati Uniti, 70508
      • Metairie, Louisiana, Stati Uniti, 70006
        • Reclutamento
        • NOLA Care Clinical Research
        • Contatto:
      • New Orleans, Louisiana, Stati Uniti, 70112
        • Reclutamento
        • Tulane University School of Medicine
        • Contatto:
    • Maryland
      • Rockville, Maryland, Stati Uniti, 20854
    • Massachusetts
      • Springfield, Massachusetts, Stati Uniti, 011030
    • Michigan
      • Troy, Michigan, Stati Uniti, 48085
        • Reclutamento
        • Oakland Medical Research Center
        • Contatto:
          • Juliejo (Julie) Clinical Research Manager
          • Numero di telefono: 248-687-7412
          • Email: juliejolafave@msn.com
    • Nebraska
      • Lincoln, Nebraska, Stati Uniti, 68510
      • Omaha, Nebraska, Stati Uniti, 68134
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89148
      • Las Vegas, Nevada, Stati Uniti, 89108
    • New York
      • Albany, New York, Stati Uniti, 12203
        • Reclutamento
        • Albany Medical College
        • Contatto:
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27514
        • Reclutamento
        • University of North Carolina at Chapel Hill
        • Contatto:
      • Greenville, North Carolina, Stati Uniti, 27834
      • Morehead City, North Carolina, Stati Uniti, 28557
      • Wilmington, North Carolina, Stati Uniti, 28401
        • Reclutamento
        • PMG Research of Wilmington, LLC
        • Contatto:
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45219
        • Reclutamento
        • Velocity Clinical Research, Cincinnati, Mt. Auburn
        • Contatto:
      • Cincinnati, Ohio, Stati Uniti, 45242
        • Reclutamento
        • Velocity Clinical Research - Cincinnati, Blue Ash
        • Contatto:
      • Columbus, Ohio, Stati Uniti, 43201
        • Reclutamento
        • Endocrinology Associates, Inc
        • Contatto:
      • Columbus, Ohio, Stati Uniti, 43215
        • Reclutamento
        • Remington Davis, Inc
        • Contatto:
    • Oregon
      • Eugene, Oregon, Stati Uniti, 97404
        • Reclutamento
        • Willamette Valley Clinical Studies
        • Contatto:
          • Patricia Manager
          • Numero di telefono: 541-461-0132
          • Email: drpatb@aol.com
    • Pennsylvania
      • West Chester, Pennsylvania, Stati Uniti, 19380
    • South Carolina
      • Anderson, South Carolina, Stati Uniti, 29621
      • Mt. Pleasant, South Carolina, Stati Uniti, 29464
    • Texas
      • Austin, Texas, Stati Uniti, 78759
      • Dallas, Texas, Stati Uniti, 75230
      • Houston, Texas, Stati Uniti, 77040
      • Lampasas, Texas, Stati Uniti, 76550
        • Reclutamento
        • Radiance Clinical Research
        • Contatto:
      • Lewisville, Texas, Stati Uniti, 75057
      • Mission, Texas, Stati Uniti, 78572
        • Reclutamento
        • Texas Valley Clinical Research - Mission, TX
        • Contatto:
      • Round Rock, Texas, Stati Uniti, 78681
        • Reclutamento
        • Texas Diabetes & Endocrinology, P.A. - Round Rock
        • Contatto:
      • San Antonio, Texas, Stati Uniti, 78229
        • Reclutamento
        • Diabetes & Glandular Disease Clinic, P.A.
        • Contatto:
      • San Antonio, Texas, Stati Uniti, 78251
        • Reclutamento
        • Texas Valley Clinical Research - San Antonio TX
        • Contatto:
      • Seabrook, Texas, Stati Uniti, 77586
      • Weslaco, Texas, Stati Uniti, 78596
        • Reclutamento
        • Texas Valley Clinical Research, LLC
        • Contatto:
    • Utah
      • West Jordan, Utah, Stati Uniti, 84088
        • Reclutamento
        • Velocity Clinical Research, Salt Lake City
        • Contatto:
    • Virginia
      • Suffolk, Virginia, Stati Uniti, 23435
      • Vienna, Virginia, Stati Uniti, 22182

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • From Screening 1

    • Age at least 18 years.

    • HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).

    • Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).

    • Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.

    • Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.

    • At least one of the following

      • ≥3 stable and adequate ADMs;
      • diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
      • hypertension requiring ≥2 adequately dosed AHMs;
      • adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
      • adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
      • evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
      • or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.

At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.

At Screening 2

  • HbA1c ≥7.5% at Screening 2. At Day 1
  • No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.

Exclusion Criteria:

  • New-onset diabetes (onset <1 year in the past).

  • Unwillingness to maintain with current glucose-lowering regimen during the trial.

  • Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.

  • Unwillingness to comply with CGM or other trial procedures.

  • Investigator considers the patient will otherwise be unwilling or unable to complete the trial.

  • Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.

  • Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).

  • Any of the following in medical history:

    • Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
    • A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
    • Hypersensitivity or severe reaction to dexamethasone;
    • Pheochromocytoma, or suspicion thereof;
    • Anorexia, or other eating disorder;
    • Glucocorticoid resistance;
    • Multiple sclerosis;
    • Significant hepatic impairment (e.g., Child-Pugh Class B or C);
    • Idiopathic thrombocytopenic purpura;
    • Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
    • Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
    • Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
    • Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
    • Any of the following in medication history:
    • Any of the excluded medications listed in Section 6.9;
    • Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
    • Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
    • Pregnancy (including a positive urine test) or current breast feeding.

From Screening 2

• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:

  • wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
  • a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
  • supraclavicular/dorsocervical fat accumulation;
  • irounding of the face (especially compared with prior photos);
  • skin changes (violaceous striae, skin thinning, or excessive bruising);
  • proximal muscle weakness on exam; or
  • history of deep vein thrombosis/pulmonary embolism.
  • Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
  • Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
  • Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
  • Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
  • Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
  • Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
  • Known hypersensitivity to clofutriben or to any of the product

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dose 1

clofutriben .2 mg oral tablet daily

HSD-1 inhibitor

Altri nomi:
  • SPI-62
  • ASP3662
Sperimentale: Dose 2

clofutriben 2mg oral tablet daily

HSD-1 inhibitor

Altri nomi:
  • SPI-62
  • ASP3662
Sperimentale: Dose 3

clofutriben 6mg oral tablet daily

HSD-1 inhibitor

Altri nomi:
  • SPI-62
  • ASP3662
Sperimentale: Dose 4

clofutriben 12 mg oral tablet daily

HSD-1 inhibitor

Altri nomi:
  • SPI-62
  • ASP3662
Comparatore placebo: placebo

placebo control oral tablet daily

Placebo

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
Lasso di tempo: 8-10 hours after the dexamethasone 1 mg dose.

To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose.

8-10 hours after the dexamethasone 1 mg dose.
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
Lasso di tempo: 24 weeks.

To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
Lasso di tempo: 24 weeks

To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
To evaluate the safety of clofutriben in participants with T2D and EC.
Lasso di tempo: From enrollment until end of trial 9 month

Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose

From enrollment until end of trial 9 month

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

29 novembre 2025

Completamento primario (Stimato)

31 dicembre 2027

Completamento dello studio (Stimato)

30 giugno 2028

Date di iscrizione allo studio

Primo inviato

30 novembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

18 dicembre 2025

Primo Inserito (Effettivo)

22 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • SPI-62-CL-2006

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .